KRAS and ovarian carcinoma: Ovarian carcinomas with KRAS or BRAF mutation are clinically low-grade carcinomas of serous or other histological subtypes that are often refractory to conventional cytotoxic chemotherapy (Bristow et al, 2002a, 2002b; Winter et al, 2007).